Description TNKase® (Tenecteplase), a thrombolytic, or clot-busting agent, works by stimulating the body's own clot-dissolving mechanism by activating plasminogen, a naturally occurring substance secreted by endothelial cells in response to injury to the artery walls that contributes to clot formation. When TNKase activates plasminogen, it converts into plasmin, which breaks down the fibrin mesh that binds the clot together.

Development Status Phase III clinical trials evaluating TNKase for restoration of function in dysfunctional central venous access catheters and dysfunctional hemodialysis catheters are ongoing.

Approved Uses

• In June 2000, the U.S. Food and Drug Administration (FDA) approved TNKase, a thrombolytic, or clot-busting agent, for the reduction of mortality associated with acute myocardial infarction (AMI), or heart attack.

Read more about TNKase's approved use.

Additional Information on Clinical Trials For inquiries about our clinical trials, please submit a request through our information request form or call (888) 662-6728.

National Institutes of Health Website: www.clinicaltrials.gov

November 2007